Trial Profile
A Multicenter Pilot Study of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 07 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2024.
- 05 Jul 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2024.